U.S. flag

An official website of the United States government

NM_000527.5(LDLR):c.337G>T (p.Glu113Ter) AND Cardiovascular phenotype

Germline classification:
Pathogenic (1 submission)
Last evaluated:
May 11, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV002453756.2

Allele description [Variation Report for NM_000527.5(LDLR):c.337G>T (p.Glu113Ter)]

NM_000527.5(LDLR):c.337G>T (p.Glu113Ter)

Gene:
LDLR:low density lipoprotein receptor [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
19p13.2
Genomic location:
Preferred name:
NM_000527.5(LDLR):c.337G>T (p.Glu113Ter)
Other names:
FH Paris-5; NP_000518.1:p.E113*
HGVS:
  • NC_000019.10:g.11105243G>T
  • NG_009060.1:g.20863G>T
  • NM_000527.5:c.337G>TMANE SELECT
  • NM_001195798.2:c.337G>T
  • NM_001195799.2:c.214G>T
  • NM_001195800.2:c.314-2149G>T
  • NM_001195803.2:c.314-1322G>T
  • NP_000518.1:p.Glu113Ter
  • NP_000518.1:p.Glu113Ter
  • NP_001182727.1:p.Glu113Ter
  • NP_001182728.1:p.Glu72Ter
  • LRG_274t1:c.337G>T
  • LRG_274:g.20863G>T
  • LRG_274p1:p.Glu113Ter
  • NC_000019.9:g.11215919G>T
  • NM_000527.4:c.337G>T
  • c.337G>T
  • p.(Glu113*)
  • p.Glu113*
Protein change:
E113*
Links:
LDLR-LOVD, British Heart Foundation: LDLR_001705;
Molecular consequence:
  • NM_001195800.2:c.314-2149G>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001195803.2:c.314-1322G>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_000527.5:c.337G>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_001195798.2:c.337G>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_001195799.2:c.214G>T - nonsense - [Sequence Ontology: SO:0001587]

Condition(s)

Name:
Cardiovascular phenotype
Identifiers:
MedGen: CN230736

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV002614438Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Pathogenic
(May 11, 2022)
germlineclinical testing

PubMed (6)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Genetic investigation of patients with hypercholesterolemia type IIa.

Szalai C, Császár A, Czinner A, Palicz T, Halmos B, Romics L.

Clin Genet. 1999 Jan;55(1):67-8. No abstract available.

PubMed [citation]
PMID:
10066037

Spectrum of LDL receptor gene mutations in Denmark: implications for molecular diagnostic strategy in heterozygous familial hypercholesterolemia.

Jensen HK, Jensen LG, Meinertz H, Hansen PS, Gregersen N, Faergeman O.

Atherosclerosis. 1999 Oct;146(2):337-44.

PubMed [citation]
PMID:
10532689
See all PubMed Citations (6)

Details of each submission

From Ambry Genetics, SCV002614438.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (6)

Description

The p.E113* pathogenic mutation (also known as c.337G>T), located in coding exon 4 of the LDLR gene, results from a G to T substitution at nucleotide position 337. This changes the amino acid from a glutamic acid to a stop codon within coding exon 4. This alteration, also known as p.E92*, has been reported in patients with familial hypercholesterolemia (FH) (Hobbs HH et al. Hum. Mutat., 1992;1:445-66; Jensen HK et al. Atherosclerosis, 1999 Oct;146:337-44; Szalai C et al. Clin. Genet., 1999 Jan;55:67-8; Weiss N et al. J. Inherit. Metab. Dis., 2000 Dec;23:778-90; Salazar LA et al. Hum. Mutat., 2002 Apr;19:462-3). This alteration has also been reported in a homozygous state in a pediatric FH cohort (Sanna C et al. Atherosclerosis, 2016 Apr;247:97-104). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 1, 2024